Present and future of EGFR inhibitors for head and neck squamous cell cancer

Journal of Oncology

Volumn , Issue , 2012, Pages

  Baba, Yuh ^a,b,c   Fujii, Masato ^b   Tokumaru, Yutaka ^b   Kato, Yasumasa ^c  

^a NASU RED CROSS HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c OHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; APOPTOSIS SIGNAL REGULATING KINASE 1; CELL ADHESION MOLECULE; CETUXIMAB; CLAUDIN 4; CLAUDIN 7; CORTACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FORKHEAD TRANSCRIPTION FACTOR; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL; PROTEIN BAD; PROTEIN KINASE B; PROTEIN KINASE B BETA; RAPAMYCIN; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; STAT3 PROTEIN; UNINDEXED DRUG; UVOMORULIN; VIMENTIN;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ATHEROSCLEROSIS; BREAST CANCER; CANCER SURVIVAL; CELL SURVIVAL; COLORECTAL CANCER; DIABETIC RETINOPATHY; DOWNSTREAM PROCESSING; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LUNG CARCINOMA; METASTASIS; MONOTHERAPY; NON INVASIVE PROCEDURE; OVARY CANCER; PANCREAS CANCER; PHOSPHOLIPID SYNTHESIS; POINT MUTATION; PROSTATE CANCER; PSORIASIS; RESTENOSIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; UPREGULATION; UTERINE CERVIX CARCINOMA;

EID: 84859772496     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/986725     Document Type: Review

References (69)

1. Cripps C., Winquist E., Devries M. C., Stys-Norman D., Gilbert R., Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer Current Oncology 2010 17 3 37 48
2. Khuri F. R., Shin D. M., Glisson B. S., Lippman S. M., Hong W. K., Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions Seminars in Oncology 2000 27 4 25 33 (Pubitemid 30643362)
3. Forastiere A., Koch W., Trotti A., Sidransky D., Head and neck cancer New England Journal of Medicine 2001 345 26 1890 1900 (Pubitemid 33716564)
4. van Houten V. M., van den Brekel M. W., Denkers F., Colnot D. R., Westerga J., van Diest P. J., Snow G. B., Brakenhoff R. H., Molecular diagnosis of head and neck cancer Recent Results in Cancer Research 2000 157 90 106
5. Ciardiello F., Tortora G., Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs European Journal of Cancer 2003 39 10 1348 1354 (Pubitemid 36773776)
6. Saranath D., Panchal R. G., Nair R., Mehta A. R., Sanghavi V. D., Deo M. G., Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer European Journal of Cancer B 1992 28 2 139 143
7. Burtness B., The role of cetuximab in the treatment of squamous cell cancer of the head and neck Expert Opinion on Biological Therapy 2005 5 8 1085 1093 (Pubitemid 41170037)
8. Carter C. A., Kelly R. J., Giaccone G., Small-molecule inhibitors of the human epidermal receptor family Expert Opinion on Investigational Drugs 2009 18 12 1829 1842
9. Sordella R., Bell D. W., Haber D. A., Settleman J., Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 2004 305 5687 1163 1167 (Pubitemid 39100331)
10. Loeffler-Ragg J., Witsch-Baumgartner M., Tzankov A., Hilbe W., Schwentner I., Sprinzl G. M., Utermann G., Zwierzina H., Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma European Journal of Cancer 2006 42 1 109 111 (Pubitemid 41814540)
11. Taguchi T., Tsukuda M., Imagawa-Ishiguro Y., Kato Y., Sano D., Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib Oncology Reports 2008 19 1 65 71 (Pubitemid 351176132)
12. Ozawa S., Kato Y., Ito S., Komori R., Shiiki N., Tsukinoki K., Ozono S., Maehata Y., Taguchi T., Imagawa-Ishiguro Y., Tsukuda M., Kubota E., Hata R. I., Restoration of BRAK/CXCl14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma Cancer Science 2009 100 11 2202 2209
13. Wong K. K., Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors Lung Cancer 2008 60 2 S10 S18
14. Baba Y., Fujii M., Tokumaru Y., Kato Y., New strategy in head and neck cancer: combination therapy targeting the PI3Kinase/Akt and EGFR signaling pathways. Hypotheses in Clinical Medicine. In press
15. Cohen E. E. W., Rosen F., Stadler W. M., Recant W., Stenson K., Huo D., Vokes E. E., Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck Journal of Clinical Oncology 2003 21 10 1980 1987 (Pubitemid 46606387)
16. Soulieres D., Senzer N. N., Vokes E. E., Hidalgo M., Agarvala S. S., Siu L. L., Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck Journal of Clinical Oncology 2004 22 1 77 85 (Pubitemid 41095117)
17. Eberhard D. A., Johnson B. E., Amler L. C., Goddard A. D., Heldens S. L., Herbst R. S., Ince W. L., Jnne P. A., Januario T., Johnson D. H., Klein P., Miller V. A., Ostland M. A., Ramies D. A., Sebisanovic D., Stinson J. A., Zhang Y. R., Seshagiri S., Hillan K. J., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib Journal of Clinical Oncology 2005 23 25 5900 5909
18. Anderson J. A., Irish J. C., McLachlin C. M., Ngan B. Y., H-ras oncogene mutation and human papillomavirus infection in oral carcinomas Archives of OtolaryngologyHead and Neck Surgery 1994 120 7 755 760 (Pubitemid 24217590)
19. Frederick B. A., Helfrich B. A., Coldren C. D., Zheng D., Chan D., Bunn P. A., Raben D., Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma Molecular Cancer Therapeutics 2007 6 6 1683 1691 (Pubitemid 46954044)
20. Kalish L. H., Kwong R. A., Cole I. E., Gallagher R. M., Sutherland R. L., Musgrove E. A., Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines Clinical Cancer Research 2004 10 22 7764 7774 (Pubitemid 39557542)
21. Timpson P., Wilson A. S., Lehrbach G. M., Sutherland R. L., Musgrove E. A., Daly R. J., Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib Cancer Research 2007 67 19 9304 9314 (Pubitemid 47535919)
22. Brognard J., Sierecki E., Gao T., Newton A. C., PHLPP and a Second Isoform, PHLPP2, Differentially Attenuate the Amplitude of Akt Signaling by Regulating Distinct Akt Isoforms Molecular Cell 2007 25 6 917 931 (Pubitemid 46436532)
23. Bellacosa A., de Feo D., Godwin A. K., Bell D. W., Cheng J. Q., Altomare D. A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., Testa J. R., Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas International Journal of Cancer 1995 64 4 280 285
24. Cheng J. Q., Ruggeri B., Klein W. M., Sonoda G., Altomare D. A., Watson D. K., Testa J. R., Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proceedings of the National Academy of Sciences of the United States of America 1996 93 8 3636 3641 (Pubitemid 26127592)
25. Carpten J. D., Faber A. L., Horn C., Donoho G. P., Briggs S. L., Robbins C. M., Hostetter G., Boguslawski S., Moses T. Y., Savage S., Uhlik M., Lin A., Du J., Qian Y. W., Zeckner D. J., Tucker-Kellogg G., Touchman J., Patel K., Mousses S., Bittner M., Schevitz R., Lai M. H. T., Blanchard K. L., Thomas J. E., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 2007 448 7152 439 444 (Pubitemid 47123510)
26. Haar E. V., Lee S. I., Bandhakavi S., Griffin T. J., Kim D. H., Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nature Cell Biology 2007 9 3 316 323 (Pubitemid 46344611)
27. Madhunapantula S. V., Sharma A., Robertson G. P., PRAS40 deregulates apoptosis in malignant melanoma Cancer Research 2007 67 8 3626 3636 (Pubitemid 46762147)
28. Inoki K., Li Y., Xu T., Guan K. L., Rheb GTpase is a direct target of TSC2 GAP activity and regulates mTOR signaling Genes and Development 2003 17 15 1829 1834 (Pubitemid 36944560)
29. Inoki K., Ouyang H., Li Y., Guan K. L., Signaling by target of rapamycin proteins in cell growth control Microbiology and Molecular Biology Reviews 2005 69 1 79 100 (Pubitemid 40358068)
30. Sarbassov D. D., Guertin D. A., Ali S. M., Sabatini D. M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 2005 307 5712 1098 1101 (Pubitemid 40262113)
31. Harrington L. S., Findlay G. M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N. R., Cheng S., Shepherd P. R., Gout I., Downes C. P., Lamb R. F., The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins Journal of Cell Biology 2004 166 2 213 223 (Pubitemid 38988774)
32. Vogt P. K., Gymnopoulos M., Hart J. R., PI 3-kinase and cancer: changing accents Current Opinion in Genetics and Development 2009 19 1 12 17
33. Gupta A. K., McKenna W. G., Weber C. N., Feldman M. D., Goldsmith J. D., Mick R., Machtay M., Rosenthal D. I., Bakanauskas V. J., Cerniglia G. J., Bernhard E. J., Weber R. S., Muschel R. J., Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction Clinical Cancer Research 2002 8 3 885 892 (Pubitemid 34742122)
34. Tsurutani J., Fukuoka J., Tsurutani H., Shih J. H., Hewitt S. M., Travis W. D., Jen J., Dennis P. A., Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors Journal of Clinical Oncology 2006 24 2 306 314 (Pubitemid 46622059)
35. Forgacs E., Biesterveld E. J., Sekido Y., Fong K., Muneer S., Wistuba I. I., Milchgrub S., Brezinschek R., Virmani A., Gazdar A. F., Minna J. D., Mutation analysis of the PTEN/MMAC1 gene in lung cancer Oncogene 1998 17 12 1557 1565 (Pubitemid 28472760)
36. Bertram J., Peacock J. W., Fazli L., Mui A. L. F., Chung S. W., Cox M. E., Monia B., Gleave M. E., Ong C. J., Loss of PTEN is associated with progression to androgen independence Prostate 2006 66 9 895 902 (Pubitemid 43849588)
37. Shayesteh L., Lu Y., Kuo W. L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G. B., Gray J. W., PlK3CA is implicated as an oncogene in ovarian cancer Nature Genetics 1999 21 1 99 102 (Pubitemid 29036292)
38. Ma Y. Y., Wei S. J., Lin Y. C., Lung J. C., Chang T. C., Whang-Peng J., Liu J. M., Yang D. M., Yang W. K., Shen C. Y., PIK3CA as an oncogene in cervical cancer Oncogene 2000 19 23 2739 2744 (Pubitemid 30339223)
39. Samuels Y., Ericson K., Oncogenic PI3K and its role in cancer Current Opinion in Oncology 2006 18 1 77 82 (Pubitemid 43740454)
40. Nakashima T., Clayman G. L., Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma Archives of OtolaryngologyHead and Neck Surgery 2000 126 8 957 961 (Pubitemid 30658294)
41. Baba Y., Tsukuda M., Mochimatsu I., Furukawa S., Kagata H., Nagashima Y., Koshika S., Imoto M., Kato Y., Cytostatic effect of inostamycin, an inhibitor of cytidine 5′-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, on oral squamous cell carcinoma cell lines Cell Biology International 2001 25 7 613 620 (Pubitemid 32692582)
42. Baba Y., Tsukuda M., Mochimatsu I., Furukawa S., Kagata H., Nagashima Y., Sakai N., Koshika S., Imoto M., Kato Y., Inostamycin, an inhibitor of cytidine 5′-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line Clinical and Experimental Metastasis 2000 18 3 273 279 (Pubitemid 32269997)
43. Cherrington J. M., Strawn L. M., Shawver L. K., New paradigms for the treatment of cancer: the role of anti-angiogenesis agents Advances in Cancer Research 2000 79 2 38 (Pubitemid 30228119)
44. Takahashi T., Ueno H., Shibuya M., VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells Oncogene 1999 18 13 2221 2230 (Pubitemid 29186923)
45. Rousseau S., Houle F., Landry J., Huot J., P38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells Oncogene 1997 15 18 2169 2177 (Pubitemid 27493906)
46. Gotink K. J., Verheul H. M. W., Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010 13 1 1 14
47. Ho Q. T., Kuo C. J., Vascular endothelial growth factor: biology and therapeutic applications International Journal of Biochemistry and Cell Biology 2007 39 7-8 1349 1357 (Pubitemid 47031045)
48. Baba Y., Kato Y., Mochimatsu I., Nagashima Y., Kurihara M., Kawano T., Taguchi T., Hata R. I., Tsukuda M., Inostamycin suppresses vascular endothelial growth factor-stimulated growth and migration of human umbilical vein endothelial cells Clinical amp; Experimental Metastasis 2004 21 5 419 425
49. Kaur J., Sawhney M., DattaGupta S., Shukla N. K., Srivastava A., Ralhan R., Clinical significance of Phosphatidyl Inositol Synthase overexpression in oral cancer BMC Cancer 2010 10, article no. 168
50. Baba Y., Kato Y., Ogawa K., Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma Cell Biology International 2010 34 2 171 175
51. Jones H. E., Dutkowski C. M., Barrow D., Harper M. E., Wakeling A. E., Nicholson R. I., New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145 International Journal of Cancer 1997 71 6 1010 1018 (Pubitemid 27252884)
52. Knowlden J. M., Hutcheson I. R., Barrow D., Gee J. M. W., Nicholson R. I., Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor Endocrinology 2005 146 11 4609 4618 (Pubitemid 41446598)
53. Choi Y. J., Rho J. K., Jeon B. S., Choi S. J., Park S. C., Lee S. S., Kim H. R., Kim C. H., Lee J. C., Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors Cancer Chemotherapy and Pharmacology 2010 66 2 381 388
54. Jones H. E., Goddard L., Gee J. M. W., Hiscox S., Rubini M., Barrow D., Knowlden J. M., Williams S., Wakeling A. E., Nicholson R. I., Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iresa) in human breast and prostate cancer cells Endocrine-Related Cancer 2004 11 4 793 814 (Pubitemid 40065552)
55. Jones H. E., Gee J. M. W., Barrow D., Tonge D., Holloway B., Nicholson R. I., Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells British Journal of Cancer 2006 95 2 172 180 (Pubitemid 44050916)
56. Barnes C. J., Ohshiro K., Rayala S. K., El-Naggar A. K., Kumar R., Insulin-like growth factor receptor as a therapeutic target in head and neck cancer Clinical Cancer Research 2007 13 14 4291 4299 (Pubitemid 47105993)
57. Slomiany M. G., Black L. A., Kibbey M. M., Tingler M. A., Day T. A., Rosenzweig S. A., Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma Cancer Letters 2007 248 2 269 279 (Pubitemid 46330562)
58. Rebucci M., Peixoto P., Dewitte A., Wattez N., De Nuncques M. A., Rezvoy N., Vautravers-Dewas C., Buisine M. P., Guerin E., Peyrat J. P., Lartigau E., Lansiaux A., Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance International Journal of Oncology 2011 38 1 189 200
59. Sriuranpong V., Park J. I., Amornphimoltham P., Patel V., Nelkin B. D., Gutkind J. S., Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system Cancer Research 2003 63 11 2948 2956 (Pubitemid 36667168)
60. Squarize C. H., Castilho R. M., Sriuranpong V., Pinto D. S., Gutkind J. S., Molecular cross-talk between the NF B and STAT3 signaling pathways in head and neck squamous cell carcinoma Neoplasia 2006 8 9 733 746 (Pubitemid 44465525)
61. Ihle N. T., Paine-Murrieta G., Berggren M. I., Baker A., Tate W. R., Wipf P., Abraham R. T., Kirkpatrick D. L., Powis G., The phosphatidylinositol-3- kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts Molecular Cancer Therapeutics 2005 4 9 1349 1357
62. Mohi M. G., Boulton C., Gu T. L., Sternberg D. W., Neuberg D., Griffin J. D., Gilliland D. G., Neel B. G., Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs Proceedings of the National Academy of Sciences of the United States of America 2004 101 9 3130 3135 (Pubitemid 38327746)
63. Birle D. C., Hedley D. W., Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts Molecular Cancer Therapeutics 2006 5 10 2494 2502 (Pubitemid 44650913)
64. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J. D., Iwata K. K., Gibson N. W., Griffin G., Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Molecular Cancer Therapeutics 2006 5 11 2676 2684 (Pubitemid 44848994)
65. Costa L. J., Gemmill R. M., Drabkin H. A., Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer Cells Urology 2007 69 3 596 602 (Pubitemid 46428416)
66. Hjelmeland A. B., Lattimore K. P., Fee B. E., Shi Q., Wickman S., Keir S. T., Hjelmeland M. D., Batt D., Bigner D. D., Friedman H. S., Rich J. N., The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion Molecular Cancer Therapeutics 2007 6 9 2449 2457 (Pubitemid 47480410)
67. Jimeno A., Kulesza P., Wheelhouse J., Chan A., Zhang X., Kincaid E., Chen R., Clark D. P., Forastiere A., Hidalgo M., Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy British Journal of Cancer 2007 96 6 952 959 (Pubitemid 46452288)
68. Li D., Shimamura T., Ji H., Chen L., Haringsma H. J., McNamara K., Liang M. C., Perera S. A., Zaghlul S., Borgman C. L., Kubo S., Takahashi M., Sun Y., Chirieac L. R., Padera R. F., Lindeman N. I., Jnne P. A., Thomas R. K., Meyerson M. L., Eck M. J., Engelman J. A., Shapiro G. I., Wong K. K., Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy Cancer Cell 2007 12 1 81 93 (Pubitemid 47001787)
69. Fan Q. W., Cheng C. K., Nicolaides T. P., Hackett C. S., Knight Z. A., Shokat K. M., Weiss W. A., A dual phosphoinositide-3-kinase /mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma Cancer Research 2007 67 17 7960 7965 (Pubitemid 47395125)